Trends in Fatal Poisoning Among Drug Users in France From 2011 to 2021: An Analysis of the DRAMES Register.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 08 2023
Historique:
medline: 31 8 2023
pubmed: 30 8 2023
entrez: 30 8 2023
Statut: epublish

Résumé

The DRAMES (Décès en Relation avec l'Abus de Médicaments Et de Substances) register is a database of drug-related deaths with the aim of identifying the psychoactive substances associated with and estimating the trends in these deaths. Our novel approach is based on the collection of data on all deaths for which toxicology experts have performed analyses. To describe drug-related deaths in France and report trends over an 11-year period. This case series used a national register to assess 4460 drug-related deaths that occurred from 2011 to 2021 in France. Data analyses were performed from January 1, 2012, to December 31, 2022. Demographic characteristics; medical and substance abuse history; forensic autopsy findings; and toxicology reports. Among the 4460 deceased individuals (mean [SD] age, 37.8 [10.5] years), the mortality rate was highest among men (sex ratio, 4.4:1). Of the deaths involving a single or predominant drug, the legal substitution product, methadone, was the leading cause of death during the entire study period, ahead of heroin-44.7% and 35.9% for methadone vs 15.8% and 21.8% for heroin in 2011 and 2021, respectively. Between 2011 and 2021, most of the drug-related deaths shifted from licit to illicit drugs, and statistically significant variations were found for buprenorphine, cocaine, heroin, methadone, and other licit opioids. Deaths related to polydrug use increased from 23.2% in 2011 to 30.6% in 2021. In this context, opioids remained associated with most deaths, with at least 1 opioid being involved in approximately 9 of 10 cases (85.9%) in 2021. However, the main trend was the dramatic increase in drug combinations with cocaine, from less than one-third of cases in 2011 (30.8%) to more than half in 2021 (57.8%). This case series assessment of 4460 drug-related deaths found that opioids used alone or in combination were the main contributor to drug-related deaths, despite having a lower prevalence than other drugs. This finding is similar to that of other countries; however, in France licit methadone was the leading cause of opioid-related deaths (ahead of heroin) during the study period. Deaths associated with use of cannabis, new psychoactive substances, and stimulants (including amphetamine-type stimulants and cocaine, especially in combination) have increased and should be closely monitored.

Identifiants

pubmed: 37647066
pii: 2808929
doi: 10.1001/jamanetworkopen.2023.31398
pmc: PMC10469283
doi:

Substances chimiques

Analgesics, Opioid 0
Heroin 70D95007SX
Methadone UC6VBE7V1Z
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2331398

Investigateurs

Chadi Abbara (C)
Delphine Allorge (D)
Jean-Claude Alvarez (JC)
Alice Ameline (A)
Aurélie Aquizerate (A)
Anne Barret (A)
Emilie Berland (E)
Célian Bertin (C)
Thierry Besnard (T)
Fabien Bevalot (F)
Camille Billet-Chatenay (C)
Emilie Bouquet (E)
Joanna Bourgine (J)
Bertrand Brunet (B)
Anne-Sylvie Caous (AS)
Alexandre Cesbron (A)
Leila Chaouachi (L)
Cécile Chevallier (C)
Marjorie Cheze (M)
Antony Citterio-Quentin (A)
Philippe Collon-Fabie (P)
Eric Dailly (E)
Amélie Daveluy (A)
Grégory Deffontaine (G)
Martine Delage (M)
Xavier Delavenne (X)
Florence Descamps (F)
Juliette Descoeur (J)
Guillaume Deslandes (G)
Marc Deveaux (M)
Bernadette Devos (B)
Christophe Doche (C)
Céline Eiden (C)
Aurélie Fouley (A)
Yvan Gaillard (Y)
Nicolas Gambier (N)
Catherine Ganière (C)
Jean-Pierre Goullé (JP)
Pascal Guerard (P)
Guillaume Hoizey (G)
Luc Humbert (L)
Laurent Imbert (L)
Marie-France Kergueris (MF)
Pascal Kintz (P)
Florian Klinzig (F)
Laurence Labat-Deveaux (L)
Bruno Lacarelle (B)
Christian Lacroix (C)
Denis Lamiable (D)
Michel Lavit (M)
Reynald Le Boisselier (R)
Anne Le Bouil (A)
Catherine Le Meur (C)
Sandrine Lefeuvre (S)
Bénédicte Lelièvre (B)
Véronique Lelong-Boulouard (V)
Anne-Sophie Lemaire-Hurtel (AS)
Juliana Lima-Tournebize (J)
Magalie Loilier (M)
Vincent Lopez (V)
Claire Martin-Molins (C)
Hélène Marty (H)
Olivier Mathieu (O)
Jean-Claude Mathieu-Daudé (JC)
Yves Mauras (Y)
Nathalie Milan (N)
Aurélie Moal (A)
Isabelle Morel (I)
Patrick Mura (P)
Anne-Laure Pelissier-Alicot (AL)
Gilbert Pépin (G)
Martine Perrin (M)
Anne Peyre (A)
Alain Pineau (A)
Rop Pok (R)
Catherine Ragoucy-Sengler (C)
Raphaël Rayer (R)
Emilie Roman (E)
Carine Roussel (C)
Anne Roussin (A)
Sandrine Sabini (S)
Elodie Saussereau (E)
Julien Scala-Bertola (J)
Pauline Sibille (P)
Michel Spadari (M)
Karine Titier (K)
Alain Turcant (A)
Pierrick Vacher (P)
Nicolas Venisse (N)
Ophélie Vieira (O)
Pascale Visinoni (P)

Références

Front Psychiatry. 2021 May 28;12:643315
pubmed: 34122176
Crit Care. 2020 May 6;24(1):195
pubmed: 32375836
Fundam Clin Pharmacol. 2021 Apr;35(2):455-465
pubmed: 32854152
Br J Clin Pharmacol. 2021 Oct;87(10):3925-3937
pubmed: 34282851
Addiction. 2007 May;102(5):761-70
pubmed: 17506153
Forensic Sci Int. 2004 Jun 10;142(2-3):161-210
pubmed: 15172079
Forensic Sci Int. 2020 Aug;313:110343
pubmed: 32563797
Am J Drug Alcohol Abuse. 2021 Nov 2;47(6):722-729
pubmed: 34670453
JAMA. 2001 Jan 3;285(1):45
pubmed: 11150107
Therapie. 2015 Mar-Apr;70(2):113-31
pubmed: 25858567
Therapie. 2020 Sep - Oct;75(5):491-502
pubmed: 31826806
Drug Test Anal. 2021 Apr;13(4):867-870
pubmed: 33217177
BMJ Open. 2015 May 29;5(5):e007629
pubmed: 26024998
BMJ. 2010 Sep 16;341:c4851
pubmed: 20847018
Addiction. 2023 Apr;118(4):771-775
pubmed: 36331523
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
pubmed: 28910830
Addiction. 2003 Apr;98(4):419-25
pubmed: 12653812
J Am Heart Assoc. 2014 Apr 23;3(2):e000638
pubmed: 24760961
Pain. 2021 Mar 1;162(3):770-777
pubmed: 33021567
Br J Clin Pharmacol. 2022 Aug;88(8):3789-3802
pubmed: 35318713
Addiction. 2022 May;117(5):1191-1192
pubmed: 35373487

Auteurs

Bruno Revol (B)

Addictovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
HP2 Laboratory, Inserm U1300, Grenoble Alpes University, Grenoble, France.

Théo Willeman (T)

Laboratory of Pharmacology, Pharmacogenetics, and Toxicology, Grenoble Alpes University Hospital, Grenoble, France.
Clinical Forensic Medicine Department, Grenoble Alpes University Hospital, Grenoble, France.

Marc Manceau (M)

Clinical Research Center, Inserm CIC1406, Grenoble Alpes University Hospital, Grenoble, France.

Véronique Dumestre-Toulet (V)

ToxGen Laboratory, Bordeaux, France.

Jean-Michel Gaulier (JM)

Toxicology Unit, Lille University Hospital, Lille, France.

Nathalie Fouilhé Sam-Laï (N)

Addictovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.

Hélène Eysseric-Guérin (H)

Laboratory of Pharmacology, Pharmacogenetics, and Toxicology, Grenoble Alpes University Hospital, Grenoble, France.
Forensic Laboratory, Grenoble Alpes University, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH